Progress in adjuvant chemotherapy for breast cancer: an overview

BMC Medicine

Joseph A. Sparano¹  Della Makower¹  Jesus Anampa¹ 

[1] Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx 10461, NY, USA

关键词: Taxanes;    Early breast cancer;    Chemotherapy;    Breast cancer;    Anthracyclines;    Adjuvant chemotherapy;   

Others  :  1222371
DOI  :  10.1186/s12916-015-0439-8

 received in 2015-04-29, accepted in 2015-07-29,  发布年份 2015

【 摘 要 】

Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes. This review summarizes key milestones in the evolution of adjuvant systemic therapy in general, and adjuvant chemotherapy in particular. Although adjuvant treatments are routinely guided by predictive factors for endocrine therapy (hormone receptor expression) and anti-HER2 therapy (HER2 overexpression), predicting benefit from chemotherapy has been more challenging. Randomized studies are now in progress utilizing multiparameter gene expression assays that may more accurately select patients most likely to benefit from adjuvant chemotherapy.

【 授权许可】

   
2015 Anampa et al.

【 参考文献 】

• [1]Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19:1893-907.
• [2]Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
• [3]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
• [4]Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. (eds). SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014. http://seer.cancer.gov/csr/1975_2011/. [Last accessed 7/28/2015.]
• [5]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28:2784-95.
• [6]Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al.. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:3997-4013.
• [7]Sparano JA, Fazzari M, Kenny PA. Clinical application of gene expression profiling in breast cancer. Surg Oncol Clin N Am. 2010; 19:581-606.
• [8]Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360:790-800.
• [9]Cotlar AM, Dubose JJ, Rose DM. History of surgery for breast cancer: radical to the sublime. Curr Surg. 2003; 60:329-37.
• [10]Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002; 347:567-75.
• [11]Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER et al.. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347:1233-41.
• [12]Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988; 319:1681-92.
• [13]Tamoxifen for early breast cancer. Cochrane Database Syst Rev. 2001; 1:CD000486.
• [14]Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-717.
• [15]Davies C, Godwin J, Gray R, Clarke M, Cutter D et al.. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378:771-84.
• [16]Peto R, Davies C, Godwin J, Gray R, Pan HC et al.. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012; 379:432-44.
• [17]Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100:8418-23.
• [18]Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L et al.. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012; 5:44.
• [19]Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al.. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27:1160-7.
• [20]Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968; 168:337-56.
• [21]Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H et al.. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975; 292:117-22.
• [22]Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C et al.. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976; 294:405-10.
• [23]Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ et al.. Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374:2055-63.
• [24]Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW et al.. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989; 320:485-90.
• [25]Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK et al.. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol. 1998; 16:3486-92.
• [26]Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL et al.. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997; 89:1673-82.
• [27]Abrams JS. Adjuvant therapy for breast cancer--results from the USA consensus conference. Breast Cancer. 2001; 8:298-304.
• [28]Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O et al.. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014; 106:11.
• [29]Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al.. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24:3726-34.
• [30]Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT et al.. Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010; 11:55-65.
• [31]Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al.. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25:5287-312.
• [32]Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer, Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983;1:257–61.
• [33]Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD et al.. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet. 1983; 2:450.
• [34]Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al.. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005; 365:60-2.
• [35]Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L et al.. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353:2747-57.
• [36]Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349:1793-802.
• [37]Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V et al.. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381:805-16.
• [38]Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I et al.. International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371:107-18.
• [39]Pagani O, Regan MM, Francis PA. Exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014; 371:1358-9.
• [40]Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al.. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673-84.
• [41]Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R et al.. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354:809-20.
• [42]Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al.. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-72.
• [43]Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al.. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365:1273-83.
• [44]Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK et al.. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015; 372:134-41.
• [45]Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I et al.. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013; 14:1121-8.
• [46]Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T et al.. PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013; 14:741-8.
• [47]Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM et al.. Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013; 382:1021-8.
• [48]Hutchinson L. Breast cancer: ALTTO: wake-up call for setting up clinical trials. Nat Rev Clin Oncol. 2013; 10:121.
• [49]Loprinzi CL, Ravdin PM. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw. 2003; 1:189-96.
• [50]Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD et al.. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005; 23:2716-25.
• [51]Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM et al.. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009; 10:1070-6.
• [52]Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997; 54:1-7.
• [53]Shockman G, Waksman SA. Rhodomycin – an antibiotic produced by a red-pigmented mutant of Streptomyces griseus. Antibiot Chemother (Northfield). 1951; 1:68-75.
• [54]Tan C, Etcubanas E, Wollner N, Rosen G, Gilladoga A, Showel J et al.. Adriamycin – an antitumor antibiotic in the treatment of neoplastic diseases. Cancer. 1973; 32:9-17.
• [55]Brambilla C, Valagussa P, Bonadonna G. Sequential combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol. 1978; 1:35-9.
• [56]Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol. 1998; 25:66-71.
• [57]Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA et al.. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986; 46:3722-7.
• [58]Ambrosini G, Balli M, Garusi G, Demicheli R, Jirillo A et al.. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol. 1988; 6:976-82.
• [59]Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971; 93:2325-7.
• [60]Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979; 277:665-7.
• [61]Horwitz SB. Personal recollections on the early development of taxol. J Nat Prod. 2004; 67:136-8.
• [62]Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ et al.. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014; 6:229ra43.
• [63]Weaver BA. How taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014; 25:2677-81.
• [64]Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995; 332:1004-14.
• [65]Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991; 83:288-91.
• [66]Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A et al.. Coping with toxicities of docetaxel (Taxotere). Ann Oncol. 1993; 4:610-1.
• [67]Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E et al.. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005; 23:5542-51.
• [68]Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK et al.. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003; 21:588-92.
• [69]Bachegowda LS, Makower DF, Sparano JA. Taxanes: impact on breast cancer therapy. Anticancer Drugs. 2014; 25:512-21.
• [70]Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983; 1:2-10.
• [71]Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L et al.. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005; 330:217.
• [72]Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N et al.. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989; 7:572-82.
• [73]Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG et al.. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990; 8:1483-96.
• [74]Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER et al.. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001; 19:931-42.
• [75]Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R et al.. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014; 32:2311-7.
• [76]Namer M, Fargeot P, Roché H, Campone M, Kerbrat P, Romestaing P et al.. French Adjuvant Study Group. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials. Ann Oncol. 2006; 17:65-73.
• [77]A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol. 1988; 6:679-88.
• [78]Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001; 19:602-11.
• [79]Sparano JA. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol. 1999; 26:14-9.
• [80]Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001; 6:30-5.
• [81]Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006; 3:406-7.
• [82]Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al.. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21:976-83.
• [83]Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B et al.. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005; 23:3686-96.
• [84]Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ et al.. NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006; 355:1851-62.
• [85]Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al.. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009; 27:1177-83.
• [86]Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noël DR, Al-Tweigeri T et al.. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001; 19:314-21.
• [87]Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S et al.. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003; 21:968-75.
• [88]Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol. 2000; 18:2369-77.
• [89]Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C et al.. Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352:2302-13.
• [90]Nabholtz JM PT, Mackey J, Pienkowski T, Pawlicki M, Guastalla JP, Vogel C et al.. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol. 2002; 21:36a.
• [91]Martin M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E et al.. GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010; 363:2200-10.
• [92]Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D et al.. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006; 24:5664-71.
• [93]Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F et al.. UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist. 2012; 17:900-9.
• [94]Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S et al.. TACT Trial Management Group; TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009; 373:1681-92.
• [95]Martin M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M et al.. GEICAM 9906 Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008; 100:805-14.
• [96]Skipper HE. Laboratory models: some historical perspective. Cancer Treat Rep. 1986; 70:3-7.
• [97]Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21:1431-9.
• [98]Hudis C, Citron M, Berry D, Cirrincione C, Gradishar W, Davidson N et al.. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium, San Antonio, TX; 2005.
• [99]Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010; 102:1845-54.
• [100]Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T et al.. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358:1663-71.
• [101]Sparano JA, Zhao F, Martino S, Ligibel J, Saphner T, Wolff AC et al.. Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX; 2014.
• [102]Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C et al.. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015; 33:58-64.
• [103]Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L et al.. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010; 362:2053-65.
• [104]Sparano JA, Solin LJ. Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making. J Clin Oncol. 2010; 28:1625-7.
• [105]Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008; 26:721-8.
• [106]Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol. 2007; 1:246-51.
• [107]National Comprehensive Cancer Network. www.nccn.org. [Last accessed 7/28/2015}]
• [108]Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M et al.. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14:461-71.
• [109]Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al.. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24:2278-84.
• [110]Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M et al.. Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26:1533-46.
• [111]Mayer EL. Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol Educ Book. 2013. p. 9–14. doi:10.1200/EdBook_AM.2013.33.9.
• [112]Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A et al.. TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013; 14:72-80.
• [113]Martin M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L et al.. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013; 31:2593-9.